Einträge von Barden, Markus auf dem Publikationsserver

Harrer, Dennis Christoph , Schlierkamp-Voosen, Tim, Barden, Markus, Pan, Hong, Xydia, Maria, Herr, Wolfgang, Dörrie, Jan, Schaft, Niels und Abken, Hinrich (2025) Chimeric Antigen Receptor (CAR) T Cells Releasing Soluble SLAMF6 Isoform 2 Gain Superior Anti-Cancer Cell Functionality in an Auto-Stimulatory Fashion. Cells 14 (12), S. 901.

Harrer, Dennis Christoph , Eder, Matthias, Barden, Markus, Pan, Hong, Herr, Wolfgang und Abken, Hinrich (2024) Ectopic PU.1 Expression Provides Chimeric Antigen Receptor (CAR) T Cells with Innate Cell Capacities Including IFN-β Release. Cancers 16 (15), S. 2737.

Harrer, Dennis Christoph , Li, Sin-Syue, Kaljanac, Marcell, Bezler, Valerie, Barden, Markus, Pan, Hong, Herr, Wolfgang und Abken, Hinrich (2024) Magnetic CAR T cell purification using an anti-G4S linker antibody. Journal of Immunological Methods 528, S. 113667.

Harrer, Dennis Christoph , Li, Sin-Syue, Kaljanac, Marcell, Barden, Markus, Pan, Hong und Abken, Hinrich (2023) Fine-tuning the antigen sensitivity of CAR T cells: emerging strategies and current challenges. Frontiers in Immunology 14.

Barden, Markus, Holzinger, Astrid, Velas, Lukas, Mezősi-Csaplár, Marianna, Szöőr, Árpád, Vereb, György, Schütz, Gerhard J., Hombach, Andreas A. und Abken, Hinrich (2023) CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation. Frontiers in Immunology 14. Volltext nicht vorhanden.

Harrer, Dennis Christoph , Schenkel, Charlotte, Bezler, Valerie, Kaljanac, Marcell, Hartley, Jordan, Barden, Markus, Pan, Hong, Holzinger, Astrid, Herr, Wolfgang und Abken, Hinrich (2022) CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine Loop. Cells 11 (23), S. 3839.

Hombach, Andreas, Barden, Markus, Hannappel, Lisa, Chmielewski, Markus, Rappl, Gunter, Sachinidis, Agapios und Abken, Hinrich (2022) IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors. Molecular Therapy 30 (2), S. 593-605. Volltext nicht vorhanden.